Peptide glossary.

BPC-157

A 15-amino-acid fragment of body protection compound studied for soft-tissue repair signalling in tendon, gut lining, and post-injury contexts.

See also: the cornerstone explainer →

CJC-1295

A long-acting analog of growth-hormone-releasing hormone (GHRH) that persists for days and raises growth-hormone levels more steadily than Sermorelin.

See also: the cornerstone explainer →

GHRP-2

A second-generation GHRP similar to GHRP-6 but with a milder hunger profile and the same GH-releasing action.

GHRP-6

A growth-hormone-releasing peptide that activates the ghrelin receptor — the original GHRP, notable for a pronounced hunger-side-effect profile.

Hexarelin

One of the most-potent GHRPs in research, with a faster desensitization window than Ipamorelin.

Ipamorelin

A selective ghrelin-receptor agonist that prompts the pituitary to release growth hormone, with the cleanest side-effect profile of the GHRP class.

See also: the cornerstone explainer →

PT-141

Bremelanotide, a melanocortin-receptor agonist that addresses libido at the CNS level rather than vascular performance like PDE5 inhibitors.

Semaglutide

A long-acting GLP-1 receptor agonist sold as Ozempic and Wegovy — the headline weight-loss peptide in the current pharmaceutical landscape.

Sermorelin

A short synthetic GHRH analog that nudges the pituitary to put out more of the body’s own growth hormone, mostly at night.

TB-500

A synthetic fragment of Thymosin Beta-4, the actin-binding protein researched for systemic soft-tissue repair, flexibility, and scar-tissue remodelling.

See also: the cornerstone explainer →

Tesamorelin

An FDA-approved GHRH analog for HIV-related lipodystrophy, studied for visceral-fat reduction outside its approved label.

Tirzepatide

A dual GLP-1 / GIP receptor agonist sold as Mounjaro and Zepbound, with the largest published weight-loss effect of any approved peptide.